Search Within

Martin Henner Voss

  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (10)
  2. Meeting Abstract (6)
  3. Research Letter (1)
Groups
  1. Department of Medicine (17)
  2. Gastrointestinal Oncology Service (17)
  3. Genitourinary Oncology Service (17)
  4. Solid Tumor Oncology Division (17)
  5. Thoracic Oncology (9)
  6. Hematologic Malignancies, Division of (8)

More Groups

People
  1. James Harding (13)
  2. Gopakumar Iyer (6)
  3. Alan Ho (4)
  4. Alexander Drilon (4)
  5. Ghassan Abou-Alfa (4)
  6. Jonathan Rosenberg (4)

More People

Years
  1. 2022 (2)
  2. 2021 (4)
  3. 2019 (3)
  4. 2018 (1)
  5. 2017 (3)
  6. 2016 (3)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Clinical Cancer Research (4)
  3. Cell (1)
  4. European Journal of Cancer (1)
  5. Genome Biology (1)
  6. Investigational New Drugs (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (4)
  3. American Medical Association (1)
  4. Biomed Central Ltd (1)
  5. Cell Press (1)
  6. Elsevier Inc. (1)

More Publishers

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial
    Journal Article

    Meric-Bernsta, F.; Tannir, N. M.; Iliopoulos, O.; Lee, R. J.; Telli, M. L.; Fan, A. C.; DeMichele, A.; Haas, N. B.; Patel, M. R.; Harding, J. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
    Journal Article

    Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
    Cell (2022)

    Fulltext@MSK | Save
  • Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care
    Meeting Abstract

    Traina, T. A.; Kantoff, P. W.; Matasar, M. J.; Dunn, L.; Friedman, C. F.; Voss, M. H.; Seidman, A. D.; Cahlon, O.; Zauderer, M. G.; Manship, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor-associated retinopathy
    Journal Article

    Francis, J. H.; Harding, J. J.; Schram, A. M.; Canestraro, J.; Haggag-Lindgren, D.; Heinemann, M.; Kriplani, A.; Jhaveri, K.; Voss, M. H.; Bajorin, D.; more...
    JAMA Ophthalmology (2021)

    Fulltext@MSK | Save
  • A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors
    Journal Article

    Harding, J. J.; Telli, M.; Munster, P.; Voss, M. H.; Infante, J. R.; DeMichele, A.; Dunphy, M.; Le, M. H.; Molineaux, C.; Orford, K.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations
    Journal Article

    Adib, E.; Klonowska, K.; Giannikou, K.; Do, K. T.; Pruitt-Thompson, S.; Bhushan, K.; Milstein, M. I.; Hedglin, J.; Kargus, K. E.; Sholl, L. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study
    Meeting Abstract

    Meric-Bernstam, F.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Tannir, N. M.; Owonikoko, T. K.; Haas, N. B.; Voss, M. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ib/II study of ramucirumab in combination with emibetuzumab in patients with advanced cancer
    Journal Article

    Harding, J. J.; Zhu, A. X.; Bauer, T. M.; Choueiri, T. K.; Drilon, A.; Voss, M. H.; Fuchs, C. S.; Abou-Alfa, G. K.; Wijayawardana, S. R.; Wang, X. A.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC)
    Meeting Abstract

    Tannir, N. M.; Fan, A. C.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Meric-Bernstam, F.; DeMichele, A.; Voss, M. H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save